- Home
- KPTI vs JHI Comparison
KPTI vs JHI Comparison
Compare KPTI & JHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- JHI
- Stock Information
- Founded
- KPTI 2008
- JHI 1971
- Country
- KPTI United States
- JHI United States
- Employees
- KPTI N/A
- JHI N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- JHI Trusts Except Educational Religious and Charitable
- Sector
- KPTI Health Care
- JHI Finance
- Exchange
- KPTI Nasdaq
- JHI Nasdaq
- Market Cap
- KPTI 44.5M
- JHI N/A
- IPO Year
- KPTI 2013
- JHI N/A
- Fundamental
- Price
- KPTI $4.61
- JHI $13.98
- Analyst Decision
- KPTI Buy
- JHI
- Analyst Count
- KPTI 6
- JHI 0
- Target Price
- KPTI $48.50
- JHI N/A
- AVG Volume (30 Days)
- KPTI 55.2K
- JHI 29.5K
- Earning Date
- KPTI 08-05-2025
- JHI 01-01-0001
- Dividend Yield
- KPTI N/A
- JHI 6.80%
- EPS Growth
- KPTI N/A
- JHI N/A
- EPS
- KPTI N/A
- JHI 1.05
- Revenue
- KPTI $142,126,000.00
- JHI N/A
- Revenue This Year
- KPTI $2.09
- JHI N/A
- Revenue Next Year
- KPTI $12.90
- JHI N/A
- P/E Ratio
- KPTI N/A
- JHI $12.47
- Revenue Growth
- KPTI 1.19
- JHI N/A
- 52 Week Low
- KPTI $3.51
- JHI $11.63
- 52 Week High
- KPTI $16.95
- JHI $13.40
- Technical
- Relative Strength Index (RSI)
- KPTI 51.08
- JHI 78.42
- Support Level
- KPTI $4.12
- JHI $13.55
- Resistance Level
- KPTI $4.64
- JHI $13.58
- Average True Range (ATR)
- KPTI 0.30
- JHI 0.11
- MACD
- KPTI 0.05
- JHI 0.04
- Stochastic Oscillator
- KPTI 67.12
- JHI 100.00
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.